Ultimovacs ASA: Invitation to first quarter 2023 results webcast presentation
May 03, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, 3 May 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter...
Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma
April 25, 2023 01:00 ET
|
Ultimovacs ASA
It is taking longer than estimated for the patients in the INITIUM study to experience disease progression, which is positive for patientsResults will be disclosed after cancer progression has been...
Ultimovacs ASA - Share Option Program
April 21, 2023 10:30 ET
|
Ultimovacs ASA
Oslo, 21 April 2023: On the basis of the approval by the General Meeting on 20 April 2023 to authorize the Board of Directors of Ultimovacs ASA (the ‘Company’, OSE ticker “ULTI”) to issue new shares...
Ultimovacs ASA – Annual General Meeting held on 20 April 2023
April 20, 2023 09:08 ET
|
Ultimovacs ASA
Oslo, 20 April 2023: Ultimovacs ASA held its annual general meeting today 20 April 2023. All the matters on the agenda were approved. All board members were re-elected for a period of one year, and...
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
April 14, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, 14 April 2023: In connection with the Annual General Meeting of Ultimovacs ASA to be held on 20 April 2023, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based...
Ultimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations
April 13, 2023 05:31 ET
|
Ultimovacs ASA
Protects UV1 vaccine-checkpoint inhibitor combinations in cancer until at least 2037Covers UV1 combined with CTLA-4, PD-1 or PD-L1 checkpoint inhibitorsNotice of intention to grant received in...
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
March 24, 2023 06:00 ET
|
Ultimovacs ASA
Oslo, 24 March 2023, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") in the meeting room ‘Jónas Einarsson auditorium’ in Ullernchausséen 64, 0379...
Ultimovacs ASA: Annual Report 2022
March 24, 2023 03:00 ET
|
Ultimovacs ASA
Oslo, 24 March 2023: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs...
Ultimovacs to Present at Cowen Healthcare Conference
February 27, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, February 27, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces today that Carlos de Sousa, Chief...
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update
February 16, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, February 16, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its fourth quarter 2022 results today. ...